Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
The clinical trial will be conducted at 19 sites with 10,335 participants across India
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Our centers are performing as expected or even better
Subscribe To Our Newsletter & Stay Updated
